Skip to Content
Merck
CN
All Photos(1)

Documents

Safety Information

485A-1

Sigma-Aldrich

ATRX Rabbit Polyclonal Antibody

Sign Into View Organizational & Contract Pricing
All Photos(1)
Synonym(s):
ATP-dependent helicase ATRX, X-linked helicase II, X-linked nuclear protein (XNP)
UNSPSC Code:
41116161

biological source

rabbit blood

Quality Level

500

conjugate

unconjugated

antibody form

IgG fraction of antiserum

antibody product type

primary antibodies

description

For In Vitro Diagnostic Use in Select Regions

form

buffered aqueous solution

species reactivity

human

packaging

vial of 0.1 mL (concentrate (485A-14))
vial of 0.1 mL (concentrate (485A-14-RUO) Research Use Only)
vial of 0.5 mL (concentrate (485A-15))
vial of 1.0 mL (concentrate (485A-16))
vial of 1.0 mL (concentrate (485A-16-RUO) Research Use Only)
vial of 1.0 mL (concentrate (485A-17-RUO) Research Use Only)
vial of 1.0 mL (pre-dilute ready-to-use (485A-17))
vial of 7.0 mL (concentrate (485A-18-RUO) Research Use Only)
vial of 7.0 mL (pre-dilute ready-to-use (485A-18))

manufacturer/tradename

Cell Marque™

technique(s)

immunocytochemistry: suitable (formalin-fixed, paraffin-embedded sections 1:50-1:50 (concentrated))

isotype

IgG

control

astrocytoma, brain, glioblastoma, oligodendroglioma

shipped in

wet ice

storage temp.

2-8°C

visualization

nuclear

General description

Diffuse gliomas are classified based on histological and molecular features to achieve an integrated diagnosis. Molecular diagnostic markers include IDH mutation, 1p/19q co-deletion, and TP53 mutation. ATRX is a chromatin remodeling protein and its mutation status may be used as a molecular diagnostic marker within the diff use glioma classification algorithm. Anti-ATRX is used to identify mutant ATRX by a loss of ATRX expression in neoplastic cells when compared with internal positive controls (endothelial cells, glia, and neurons). Grade II/III astrocytoma classification includes IDH mutant, ATRX mutant, and 1p/19q retention, while grade II/III oligodendroglioma includes IDH mutant, ATRX wildtype, and 1p/19q co-deletion; p53 expression may also serve as an aid in diagnosis. ATRX mutation is frequently, but not always, mutually exclusive with 1p/19q co-deletion.

Quality

United States - IVD
Canada - RUO
European Union - IVD
Japan - RUO

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide.

Preparation Note

Download the IFU specific to your product lot and format
Note: This requires a keycode which can be found on your packaging or product label.

Other Notes

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Legal Information

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

WGK

WGK 2

Regulatory Information

监管及禁止进口产品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Daniel J Brat et al.
The New England journal of medicine, 372(26), 2481-2498 (2015-06-11)
Diffuse low-grade and intermediate-grade gliomas (which together make up the lower-grade gliomas, World Health Organization grades II and III) have highly variable clinical behavior that is not adequately predicted on the basis of histologic class. Some are indolent; others quickly
Akane Yamamichi et al.
Brain tumor pathology, 35(2), 106-113 (2018-03-20)
The IDH-mutant and 1p/19q co-deletion (1p19q codel) provides significant diagnostic and prognostic value in lower-grade gliomas. As ATRX mutation and 1p19q codel are mutually exclusive, ATRX immunohistochemistry (IHC) may substitute for 1p19q codel, but this has not been comprehensively examined.
Matthew D Wood et al.
Diagnostic pathology, 14(1), 29-29 (2019-04-11)
Insights into the molecular underpinnings of primary central nervous system tumors have radically changed the approach to tumor diagnosis and classification. Diagnostic emphasis has shifted from the morphology of a tumor under the microscope to an integrated approach based on
Masako Ikemura et al.
Histopathology, 69(2), 260-267 (2016-01-08)
We performed an immunohistochemical analysis of alpha-thalassaemia/mental retardation syndrome X-linked (ATRX) expression in adult diffuse gliomas, with reference to clinicopathological and genetic features, to determine the utility of this analysis in diagnostic practice. A total of 193 adult diffuse gliomas
David E Reuss et al.
Acta neuropathologica, 129(1), 133-146 (2014-11-28)
Diffuse gliomas are represented in the 2007 WHO classification as astrocytomas, oligoastrocytomas and oligodendrogliomas of grades II and III and glioblastomas WHO grade IV. Molecular data on these tumors have a major impact on prognosis and therapy of the patients.
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service